18 completed, 1 recruiting, 1 unknown. 11 Not applicable, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 11 | Completed 10, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 1 | Completed 1 |
Follow Pulmonary edema of mountaineers: new trials by email Literature Review of Pulmonary edema of mountaineers trials Research Report on Pulmonary edema of mountaineers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m) Echocardiography - High Altitude Pulmonary Hypertension | Not applicable | Completed | University of Zurich | 24 | 2024-07-02 | 2026-01-21 |
| High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), 6MWT Assessed at High Altitude (3200m) vs Low Altitude (760m) 6-minute walk test (6MWT) - High Altitude Pulmonary Hypertension | Not applicable | Completed | University of Zurich | 24 | 2024-07-02 | 2026-01-22 |
| High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), SDB Assessed at HA (3200 m) vs LA (760 m) SDB assessment - High Altitude Pulmonary Hypertension | Not applicable | Completed | University of Zurich | 24 | 2024-07-02 | 2026-01-22 |
| HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders. High Altitude Pulmonary Hypertension, Sleep Apnea | Unknown | University of Zurich | 120 | 2024-07-01 | 2024-07-08 | |
| Highlanders With High Altitude Pulmonary Hypertension (HAPH), 6 Minute Walk Distance (6MWD) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT) 6-minute walk test (6MWT) - High Altitude Pulmonary Hypertension | Not applicable | Completed | University of Zurich | 24 | 2024-07-01 | 2026-01-21 |
| Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT) Echocardiography - High Altitude Pulmonary Hypertension | Not applicable | Completed | University of Zurich | 48 | 2024-07-01 | 2025-12-04 |
| Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE) Nitric Oxide Generation and Delivery System - High Altitude Pulmonary Hypertension | Not applicable | Recruiting | Novlead Inc. | 100 | 2023-08-10 | 2025-02-28 |
| Maximal Exercise Capacity at 2500 m of High Altitude Maximal Exercise Capacity - High Altitude Pulmonary Hypertension, Maximal Exercise Capacity | Not applicable | Completed | University of Zurich | 28 | 2021-10-20 | 2022-05-11 |
| Altitude Related Adverse Health Effects (ARAHE) in Patients With Precapillary Pulmonary Hypertension During 30h Exposure to 2500m Stay at altitude 2500 m above sea level (high altitude), Stay at altitude 470 m above sea level (low altitude) - High Altitude Pulmonary Hypertension | Not applicable | Completed | University of Zurich | 28 | 2021-10-18 | 2022-05-11 |
| Exercise Endurance Time on the 2nd Day at 2500 m High Altitude High altitude exposure, Low altitude exposure - High Altitude Pulmonary Hypertension | Not applicable | Completed | University of Zurich | 28 | 2021-10-18 | 2022-05-11 |
| Nocturnal Oxygenation and Sleep-related Breathing Disorders During the First Night of a Stay at 2500m of High Altitude in Patients With Precapillary Pulmonary Hypertension Nocturnal rest (sleep study) - High Altitude Pulmonary Hypertension, Sleep | Not applicable | Completed | University of Zurich | 28 | 2021-10-18 | 2022-05-11 |
| Effect of Oxygen Therapy for Patients With Precapillary Pulmonary Hypertension Who Experience an Altitude Related Adverse Health Effect (ARAHE) During 30h Exposure to 2500m Oxygen Therapy - High Altitude Pulmonary Hypertension, Oxygen Therapy | Not applicable | Completed | University of Zurich | 9 | 2021-10-18 | 2022-05-11 |
| Cerebral Tissue Oxygenation in Highlanders/Lowlanders High Altitude Pulmonary Hypertension | Completed | University of Zurich | 79 | 2017-05-24 | 2019-08-16 | |
| Right Ventricular Function During Exercise in Highlanders/Lowlanders High Altitude Pulmonary Hypertension | Completed | University of Zurich | 173 | 2017-05-24 | 2019-08-16 | |
| Right Ventricular Function at Rest in Highlanders/Lowlanders High Altitude Pulmonary Hypertension | Completed | University of Zurich | 173 | 2017-05-24 | 2019-08-16 | |
| Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders. High Altitude Pulmonary Hypertension, Sleep Apnea | Completed | University of Zurich | 165 | 2017-05-24 | 2019-08-16 | |
| Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude Riociguat - Hypertension, Pulmonary, Altitude Sickness | Phase 4 | Completed | Richard Moon | 28 | 2014-01-01 | 2017-04-12 |
| Sleep Related Breathing Disturbances and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders High Altitude Pulmonary Hypertension, Sleep Apnea | Completed | University of Zurich | 125 | 2012-06-01 | 2014-05-15 | |
| The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension Theophylline and Bambuterol - High Altitude Pulmonary Hypertension | Phase 1 | Completed | Norwegian Armed Forces Medical Service | 20 | 2012-03-01 | 2013-02-26 |
| The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers Aminophylline, Ambrisentan, Aminophylline plus ambrisentan - High Altitude Pulmonary Hypertension | Phase 1 | Completed | Thies Schroeder | 18 | 2012-02-01 | 2014-01-16 |
Hypertension, Pulmonary (12) · Hypoxia (11) · Altitude Sickness (6) · Disease Progression (4) · Sleep Apnea Syndromes (4) · Motor Activity (1)
Cardiovascular Diseases (12) · Hypertension (12) · Lung Diseases (12) · Respiratory Tract Diseases (12) · Vascular Diseases (12) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (11) · Signs and Symptoms, Respiratory (11) · Respiration Disorders (9) · Apnea (4) · Disease Attributes (4) · Dyssomnias (4) · Nervous System Diseases (4) · Pathologic Processes (4) · Sleep Disorders, Intrinsic (4)
Aminophylline (1) · Oxygen (1) · Theophylline (1) · ambrisentan (1) · bambuterol (1) · riociguat (1)
University of Zurich (16) · Norwegian Armed Forces Medical Service (1) · Novlead Inc. (1) · Richard Moon (1) · Thies Schroeder (1)
Kyrgyzstan (10) · Switzerland (5) · United States (2) · China (1) · Norway (1)
Silvia Ulrich, Prof. Dr. (6) · Talant M Sooronbaev, Prof. Dr. (4) · Talant M Sooronbaev, MD (3) · Talant MA Sooronbaev, Prof. Dr. (2) · Jingxin Cao (1) · Konrad E Bloch, MD (1) · Richard E Moon, MD (1) · Robert J Noveck, MD (1) · Talant Sooronbaev, MD (1) · Thies Schroeder, Ph.D. (1) · Trond-Eirik Strand, M.D., Ph.D. (1)
PMID 38079468, PMID 32430415, PMID 40085143, PMID 40404280, PMID 42398808, PMID 42823120